RSS Updates
Email Updates
Genentech’s (DNA) for Q2 hit $3 billion, up from $2.2 billion in the same quarter last year. Operating income hit $1.1 billion up from $.75 billion last year.
Big winners in the company’s drug portfolio were Avastin with sales up 33% to $564 million in US product sales and Lucentis, introduced recently with sales of $209 million.
Sales of the company’s No.1 product, Rituxan, were up 11% to $562.
The shares traded flat after hours.
Douglas A. McIntyre
An
Buzz up!
Digg
Fark
Facebook
Tip'd
